Activating Death Receptor DR5 as a Therapeutic Strategy for Rhabdomyosarcoma.

ISRN Oncology
Zhigang KangLiang Cao

Abstract

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. It is believed to arise from skeletal muscle progenitors, preserving the expression of genes critical for embryonic myogenic development such as MYOD1 and myogenin. RMS is classified as embryonal, which is more common in younger children, or alveolar, which is more prevalent in elder children and adults. Despite aggressive management including surgery, radiation, and chemotherapy, the outcome for children with metastatic RMS is dismal, and the prognosis has remained unchanged for decades. Apoptosis is a highly regulated process critical for embryonic development and tissue and organ homeostasis. Like other types of cancers, RMS develops by evading intrinsic apoptosis via mutations in the p53 tumor suppressor gene. However, the ability to induce apoptosis via the death receptor-dependent extrinsic pathway remains largely intact in tumors with p53 mutations. This paper focuses on activating extrinsic apoptosis as a therapeutic strategy for RMS by targeting the death receptor DR5 with a recombinant TRAIL ligand or agonistic antibodies directed against DR5.

References

Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·L M MulliganW K Cavenee
Jun 1, 1995·Cancer Metastasis Reviews·J M Lee, A Bernstein
Aug 26, 1993·Nature·J OgasawaraS Nagata
Apr 1, 1995·The Journal of Clinical Investigation·L DillerD Malkin
Aug 29, 1997·The Journal of Experimental Medicine·S MandruzzatoP van der Bruggen
May 2, 1998·The EMBO Journal·C ScaffidiM E Peter
Jan 27, 2000·Cell·D Hanahan, R A Weinberg
Aug 10, 2000·Neoplasia : an International Journal for Oncology Research·A M Chinnaiyan
Sep 27, 2000·International Journal of Cancer. Journal International Du Cancer·F Van ValenH Jürgens
Dec 1, 2000·Nature·B VogelsteinA J Levine
Jun 26, 2001·Cell Death and Differentiation·H U KontnyC M Niemeyer
Oct 5, 2001·The Journal of Biological Chemistry·F C KischkelA Ashkenazi
Aug 3, 2002·Nature Reviews. Cancer·Karen H Vousden, Xin Lu
Oct 31, 2002·Neoplasia : an International Journal for Oncology Research·Nesrin Ozören, Wafik S El-Deiry
Dec 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John C BrenemanWilliam M Crist
Sep 2, 2003·Gastroenterology·Hong Sug KimSug Hyung Lee
Dec 10, 2003·Oncogene·Jordan S Fridman, Scott W Lowe
Apr 13, 2004·Oncogene·Judith Henry-MowattDominic James
Oct 12, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kamel IzeradjeneJanet A Houghton
Nov 19, 2004·Nature·Scott W LoweGerard Evan
Feb 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel WilliamsonJanet Shipley
May 14, 2005·CA: a Cancer Journal for Clinicians·Irene M GhobrialAlex A Adjei
Oct 4, 2005·The Journal of Clinical Investigation·Anthony Letai
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jane L MezaUNKNOWN Children's Oncology Group
Feb 3, 2007·The EMBO Journal·Anni I NieminenJuha Klefstrom

❮ Previous
Next ❯

Citations

May 15, 2018·International Journal of Molecular Sciences·Ana Gallego-LleydaLuis Martinez-Lostao

❮ Previous
Next ❯

Methods Mentioned

BETA
ubiquitination
xenograft

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis